La bourse ferme dans 1 h 18 min

Quantum Genomics Société Anonyme (ALQGC.PA)

Paris - Paris Prix différé. Devise en EUR
Ajouter à la liste dynamique
4,3450-0,0700 (-1,59 %)
À partir de 3:57PM CET. Marché ouvert.
Plein écran
Clôture précédente4,4150
Ouverture4,4000
Offre0,0000 x 0
Vente0,0000 x 0
Var. jour4,2800 - 4,4800
Sur 52 semaines1,5100 - 5,6800
Volume377 632
Volume moyen735 423
Cap. boursière115,894M
Bêta (mensuel sur 5 ans)0,91
Rapport P/E (sur 12 mois)S.O.
BPA (sur 12 mois)-0,4940
Date de bénéficesS.O.
Dividende et rendement à termeS.O. (S.O.)
Date ex-dividendeS.O.
Objectif sur 1 an9,86
  • Globe Newswire

    Quantum Genomics Launches Phase III Pivotal REFRESH Study in Difficult-to-treat/Resistant Hypertension with Once-a-day Formulation of Firibastat

    PARIS and NEW YORK, Jan. 18, 2021 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in developing a new drug class that directly targets the brain to treat difficult-to-treat and resistant hypertension and heart failure today announced the launch of its Phase III REFRESH study in difficult-to-treat(1) or resistant(2) hypertension. This new study is part of firibastat’s Phase III clinical development and aims to assess long-term safety as well as the three-month efficacy after a single daily dose of firibastat 1000mg in treatment resistant hypertensive patients. “We are thrilled to launch this new pivotal study as a precursor to potential market approval of single dose firibastat, which we believe to be the best regimen for chronic treatment of resistant of difficult-to-treat hypertension,” said Jean-Philippe Milon, Chief Executive Officer at Quantum Genomics. “This study will also provide long-term safety data in accordance with Quantum Genomics’ development plan endorsed by the FDA.” (3) This multicenter, multinational study will enroll 750 patients with difficult-to-treat or resistant hypertension in Europe, Canada, US as well as collaboratively in Asia with our commercial partners in China, Taiwan and South-Korea. For the first randomized three-month period, 750 patients will receive firibastat (1000mg once-a-day) or placebo, on top of their current therapy. The primary endpoint will be reduction in systolic automated office blood pressure (AOBP) from baseline. After this first period, subjects will be treated and followed-up for six months (and 12 months for 100 patients) to assess long-term safety, data that are mandatory for New Drug Application (NDA) for a chronic treatment. Sites selection will start shortly, and regulatory submissions to competent authorities and ethics committees are in preparation for each country. First patient recruitment is planned in Q2 2021 and efficacy results and six-month safety results are expected for mid-2023, on time to submit New Drug Applications in 2023. Study costs are budgeted and financed thanks to the partnerships signed by Quantum Genomics. (1) Patients not controlled despite two antihypertensive classes, including a diuretic, at maximum tolerated doses.(2) Patients not controlled despite at least three antihypertensive classes, including a diuretic, at maximum tolerated doses.(3) FDA: Food and Drug Administration, US Regulatory Authority. About Quantum Genomics Quantum Genomics is a biopharmaceutical company specializing in the development of a new class of cardiovascular medications based on brain aminopeptidase A inhibition (BAPAI). Quantum Genomics is the only company in the world exploring this innovative approach that directly targets the brain. The company relies on 20 years of academic research from the Paris-Descartes University and the laboratory directed by Dr. Catherine Llorens-Cortes at the Collège de France (French National Institute of Health and Medical Research (INSERM)/ the Scientific Centre for National Research (CNRS)). The goal of Quantum Genomics is to develop innovative treatments for complicated, or even resistant, cases of hypertension (around 30% of patients have poor control of their condition or receive ineffective treatment) and for heart failure (one in two patients diagnosed with severe heart failure dies within five years). Based in Paris and New York, Quantum Genomics is listed on the Euronext Growth exchange in Paris (FR0011648971- ALQGC) and trades on the OTCQX Best Market in the United States (symbol: QNNTF). For more information, please visit www.quantum-genomics.com, or follow us on Twitter and LinkedIn Contact Quantum Genomics Contact@quantum-genomics.fr So Bang (Europe) Financial and Media communicationQuantum-genomics@so-bang.fr LifeSci (USA) Dan FerryFinancial Communications+1 (617) 430-7576 | Daniel@lifesciadvisors.comMike TattoryMedia Relations and Scientific Communications+1 (609) 802-6265 | mtattory@lifescicomms.com

  • Globe Newswire

    Quantum Genomics Signs a Strategic Contract with Delpharm

    Delpharm Group selected for large-scale production of firibastat tablets to support clinical phase and future commercial needsPARIS and NEW YORK, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in the development of a new class of drugs acting directly on the brain to treat difficult-to-treat / resistant hypertension and heart failure, announces today that it has signed a strategic contract with Delpharm for the manufacture of the next clinical batches of firibastat tablets on an industrial scale and the establishment of production lines for future commercial batches. The efficacy of firibastat, the first drug-candidate of the class of brain aminopeptidase A inhibitors, is currently being evaluated in an international phase III clinical trial (FRESH study) in uncontrolled hypertensive patients despite a treatment comprising at least two classes of antihypertensive drugs including a diuretic, and in a phase II clinical trial (QUORUM study) in patients after myocardial infarction. "We are very pleased to entrust the production of future firibastat tablets to Delpharm, whose expertise in pharmaceutical development and size with its numerous production sites make it one of the European leaders in the sector. For more than 30 years, Delpharm team has built a solid reputation as a drug producer serving the most demanding pharmaceutical companies and groups," declared Fabrice Balavoine, Vice-President Research and Development of Quantum Genomics. "Delpharm is very proud to support the company Quantum Genomics in its clinical trials and in manufacturing future commercial batches of firibastat in order to help patients suffering from resistant arterial hypertension or heart failure to rapidly access this promising new treatment," adds Nicolas Ragot, Chief Operating Officer at Delpharm. About Delpharm Delpharm is a European leader in contract manufacturing and development of medicines for pharmaceutical companies, generating € 800m turnover and is wholly owned by its management. Delpharm operates 17 manufacturing plants across Europe and Canada providing the majority of dosage forms available on the market, clinical batches manufacturing for Phases 1-3, and full development services. Additional information on Delpharm can be found at www.delpharm.com. About Quantum Genomics Quantum Genomics is a biopharmaceutical company specializing in the development of a new class of cardiovascular medications based on brain aminopeptidase A inhibition (BAPAI). Quantum Genomics is the only company in the world exploring this innovative approach that directly targets the brain. The company relies on 20 years of academic research from the Paris-Descartes University and the laboratory directed by Dr. Catherine Llorens-Cortes at the Collège de France (French National Institute of Health and Medical Research (INSERM)/ the Scientific Centre for National Research (CNRS)). The goal of Quantum Genomics is to develop innovative treatments for complicated, or even resistant, cases of hypertension (around 30% of patients have poor control of their condition or receive ineffective treatment) and for heart failure (one in two patients diagnosed with severe heart failure dies within five years). Based in Paris and New York, Quantum Genomics is listed on the Euronext Growth exchange in Paris (FR0011648971- ALQGC) and trades on the OTCQX Best Market in the United States (symbol: QNNTF). For more information, please visit www.quantum-genomics.com, or follow us on Twitter and LinkedIn Contact information Quantum Genomics Jean-Philippe MilonCEOjean-philippe.milon@quantum-genomics.comBenoît GueugnonCFO benoit.gueugnon@quantum-genomics.comSo Bang (Europe)  Nathalie BoumendilFinancial Communications +33 (0)6 85 82 41 95 | nathalie@so-bang.frSamuel BeaupainMedia Relations and Scientific Communications+33 (0)6 88 48 48 02 | samuel@so-bang.frLifeSci (USA) Dan FerryFinancial Communications +1 (617) 430-7576 | Daniel@lifesciadvisors.comMike TattoryMedia Relations and Scientific Communications+1 (609) 802-6265 | mtattory@lifescicomms.com

  • Globe Newswire

    Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with Faran

    Quantum Genomics to receive up to $12.1 million in upfront and milestone payments plus double-digit royalties on sales Faran to receive an exclusive license to develop and commercialize firibastat for the treatment of difficult to treat/resistant hypertension in Greece PARIS and NEW YORK, Dec. 15, 2020 (GLOBE NEWSWIRE) --  Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in developing a new drug class that directly targets the brain to treat difficult to treat/resistant hypertension today announced it has entered into an exclusive licensing and collaboration agreement with Faran to develop and commercialize firibastat in Greece. This new agreement is the first step of Quantum Genomics’ partnering strategy in Europe. Under the terms of the agreement, Faran will receive exclusive commercialization rights to firibastat for the treatment of difficult to treat/resistant hypertension in Greece. Additionally, Faran may join the global  study of difficult to treat/resistant hypertension in Greece. Quantum Genomics will receive upfront and milestone payments amounting up to $12.1 million, plus double-digit royalties on sales. Over 20% of the adult general population in Greece suffers of Hypertension. Resistant hypertension is a common disorder with an estimated prevalence of more than 10% in the general hypertensive population. “Faran who was established 70 years ago is one of the leading player in Greece. Having many long lasting partnerships with global pharmaceutical companies, Faran is focusing on eight innovative products and through an extended partnership with five more original products at Cardiology segment. We had intensive discussions with well experienced people and we are excited to partner firibastat with Faran in Greece," mentionned Jean-Philippe Milon, Chief Executive Officer of Quantum Genomics. "Faran is investing and focusing on Cardiology, with a clear vision to become local market leader. We are very enthusiastic to establish a partnership with Quantum Genomics," mentionned Mr Mario Katsikas, President & CEO of FARAN S.A..   About Faran Faran is a Greek pharmaceutical company that aims to offer renowned High Quality therapeutic products, with High Therapeutic Value, Modern Pharmaceutical Technology and Documented Safety. To achieve this goal our horizons expanded daily with selected international partnerships and the trust of medical community by providing therapeutic solutions in a wide range of diseases in the area of Cardiology, Oncology, Haematology, Nephrology, Orthopaedics, Rheumatology, Endocrinology, International Medicine and Gynecology. The people of Faran have in-depth knowledge of all the needs and specificities of the Greek Pharmaceutical Market and interested in health issues those concern citizens, healthcare professionals and insurance funds. They are qualitative and modern, direct and flexible. About Quantum Genomics Quantum Genomics is a biopharmaceutical company specializing in the development of a new class of cardiovascular medications based on brain aminopeptidase A inhibition (BAPAI). Quantum Genomics is the only company in the world exploring this innovative approach that directly targets the brain. The company relies on 20 years of academic research from the Paris-Descartes University and the laboratory directed by Dr. Catherine Llorens-Cortes at the Collège de France (French National Institute of Health and Medical Research (INSERM)/ the Scientific Centre for National Research (CNRS)). The goal of Quantum Genomics is to develop innovative treatments for complicated, or even resistant, cases of hypertension (around 30% of patients have poor control of their condition or receive ineffective treatment) and for heart failure (one in two patients diagnosed with severe heart failure dies within five years). Based in Paris and New York, Quantum Genomics is listed on the Euronext Growth exchange in Paris (FR0011648971- ALQGC) and trades on the OTCQX Best Market in the United States (symbol: QNNTF). For more information, please visit www.quantum-genomics.com, or follow us on Twitter and LinkedIn Contact information Quantum Genomics Jean-Philippe MilonBenoît GueugnonCEOCFOjean-philippe.milon@quantum-genomics.com benoit.gueugnon@quantum-genomics.com   So Bang (Europe)  Nathalie BoumendilSamuel BeaupainFinancial CommunicationsMedia Relations and Scientific Communications+33 (0)6 85 82 41 95 | nathalie@so-bang.fr +33 (0)6 88 48 48 02 | samuel@so-bang.fr   LifeSci (USA) Dan FerryMike TattoryFinancial CommunicationsMedia Relations and Scientific Communications+1 (617) 430-7576 | Daniel@lifesciadvisors.com +1 (609) 802-6265 | mtattory@lifescicomms.com